Who could replace Zimmer Biomet’s CEO?

July 13, 2017 By Chris Newmarker

Stephen MacMillan, CEO of Hologic

[Image from MacMillan’s LinkedIn page]

The value of Hologic’s stock has more than doubled to around $45 per share since late 2013, when Stephen MacMillan took over as CEO of the Marlborough, Mass.–based maker of medical imaging systems, diagnostic products and surgical products. Its stock has also outperformed the Russell 1000 Index and the S&P Health Care Supplies Index, according to Hologic’s annual report.

MacMillan might be the type of rainmaker Zimmer Biomet’s board desires. Plus, he was CEO at arch rival Stryker from 2003 to 2012, so he is well acquainted with the orthopedics industry.

Wells Fargo analyst Larry Biegelsen has MacMillan on his list of potential candidates.